- Home
- AVTX
as 11-22-2024 4:00pm EST
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 90.9M | IPO Year: | 2015 |
| Target Price: | $35.00 | AVG Volume (30 days): | 59.3K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -75.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.95 - $34.46 | Next Earning Date: | 11-07-2024 |
| Revenue: | $820,000 | Revenue Growth: | -63.54% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Avalo Therapeutics Inc. News
AVTX Breaking Stock News: Dive into AVTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
GlobeNewswire
12 days ago
Avalo Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire
16 days ago
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates
GlobeNewswire
a month ago
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
GlobeNewswire
3 months ago
Avalo Announces Participation in September Investor Conferences
GlobeNewswire
3 months ago
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
4 months ago
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
GlobeNewswire
4 months ago
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
Compare AVTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AVTX Avalo Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.